In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa

Diagnostic Microbiology and Infectious Disease

Volumn 46, Issue 2, 2003, Pages 131-137

  Burgess, David S ^a,b   Hall, Ronald G ^a,b   Hardin, Thomas C ^a,b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN; TAZOBACTAM; TOBRAMYCIN;

ANTIMICROBIAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; EVALUATION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0038172602     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00036-1     Document Type: Conference Paper

References (34)

1. Arnoff S.C., Klinger J.D. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia from children with cystic fibrosis. Antimicrob Agents Chemother. 25:1984;279-280.
2. Hospital-acquired pneumonia in adults diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: a consensus statement . Am J Respir Crit Care Med. 153:1996;1711-1725.
3. Bosso J.A., Saxon B.A., Matsen J.M. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob Agents Chemother. 34:1990;487-488.
4. Bosso J.A., Saxon B.A., Matsen J.M. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob Agents Chemother. 31:1987;1403-1405.
5. Burgess D.S., Nathisuwan S. Piperacillin/tazobactam, cefepime, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Micro Infect Dis. 44:2002;35-41.
6. Burgess D.S., Hastings R.W. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. Diagn Micro Infect Dis. 38:2000;37-41.
7. Burgess D.S., Hastings R.W., Hardin T.C. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Therap. 22:2000;66-75.
8. Burgess D.S., Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam by continuous infusion and intermittent dosing. Clin Therap. 24:2002;1090-1104.
9. Bustamante C.I., Wharton R.C., Wade J.C. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 34:1990;1814-1815.
10. Cappelletty D.M., Rybak M.J. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 40:1996;677-683.
11. Carmeli Y., Troillet N., Karchmer A.W., Samore M.H. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 159:1999;1127-1132.
12. Fink M.P., Snydman D.R., Niederman M.S., Leeper K.V., Johnson R.H., Heard S.O., Wunderink R.G., Caldwell J.W., Schentag J.J., Siami G.A. Treatment of severe pneumonia in hospitalized patients results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilistatin . Antimicrob Agents Chemother. 38:1994;547-557.
13. Chan E.L., Zabransky R.J. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas. Diagn Microbiol Infect Dis. 6:1987;157-164.
14. Chien S.C., Rogge M.C., Gisclon L.G., Curtin C., Wong F., Natarajan J., Williams R.R., Fowler C.L., Cheung W.K., Chow A.T. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 41:1997;2256-2260.
15. Chow A.T., Fowler C., Williams R.R., Morgan N., Kaminski S., Natarajan J. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 45:2001;2122-2125.
16. Gould I.M., Milne K. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin. J Antimicrob Chemother. 39:1997;53-61.
17. Drusano G.L., Standiford H.C., Bustamante C., Forrest A., Rivera G., Leslie J., Tatem B., Delaportas D., MacGregor R.R., Schimpff S.C. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother. 26:1984;715-721.
18. Hilf M., Yu V.L., Sharp J., Zuravleff J.J., Korvick J.A., Muder R.R. Antibiotic therapy for Pseudomonas aeruginosa bacteremia outcome correlations in a prospective study of 200 patients . Am J Med. 87:1989;540-546.
19. Isenberg H.D., Alperstein P., France K. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with β-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diagn Micro Infect Dis. 33:1999;81-86.
20. Kelpser M.E., Patel K.B., Nicolau D.P., Quintiliani R., Nightingale C.H. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 39:1995;2503-2510.
21. Korvick J.A., Yu V.L. Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemotherapy. 35:1991;2167-2172.
22. Leroy A., Leguy F., Borsa F., Spencer G.R., Fillastre J.P., Humbert G. Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother. 25:1984;638-642.
23. LEVAQUIN® (levofloxacin tablets/injection) Tablets/Injection. Package Insert. Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ 08869. REVISED November 2000.
24. Mayer I., Nagy E. Investigation of the synergistic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother. 43:1999;651-657.
25. th Ed. Approved Standard Document M7-A5. Wayne, PA: NCCLS.
26. Niederman M.S. An approach to empric therapy of nosocomial pneumonia. Medical Clinics of North America. 78:1994;1123-1141.
27. Norden S.W., Wentzel H., Keleti E. Comparison of techniques for measurement of in vitro antibiotic synergy. J Infect Dis. 140:1979;629-633.
28. Pendland S.L., Messick C.R., Jung R. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Micro Infect Dis. 42:2002;75-78.
29. Pohlman J.K., Knapp C.C., Ludwig M.D., Washington J.A. Timed killing kinetic studies of the interactions between ciprofloxacin and β-lactams against gram-negative bacilli. Diagn Micro Infect Dis. 26:1996;29-33.
30. Troillet N., Samore M.H., Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa risk factors and antibiotic susceptibility patterns . Clin Infect Dis. 25:1997;1094-1098.
31. Visalli M.A., Jacobs M.R., Appelbaum P.C. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother. 42:1998;953-955.
32. Watanakunakorn C. In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 24:1983;305-306.
33. White R.L., Burgess D.S., Manduru M., Bosso J.A. Comparison of three different in vitro methods of detecting synergy Time-kill, checkerboard, and E test . Antimicrob Agents Chemother. 40:1996;1914-1918.
34. Yorassowsky E., Van der Linden M.P., Crokaert F., Glupczynski Y. Effect of antibiotic carry-over on bacterial counting by "spiral plating" J Antimicrob Chemother. 21:1988;138-140.